IDEAYA Biosciences and Servier announced that their Phase 2/3 trial showed darovasertib combined with crizotinib significantly improved median progression-free survival (PFS) to 6.9 months versus 3.1 months with investigator's choice therapy in first-line metastatic uveal melanoma patients. The combination also showed higher response and disease control rates with manageable safety. Overall survival data is immature but trends favor the new combo. IDEAYA plans to complete FDA NDA filing in H2 2026 under an accelerated review program, potentially offering a new treatment standard for this rare cancer.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
